Denosumab, a RANK ligand inhibitor, is primarily used to prevent osteoclastogenesis in the treatment of conditions such as osteoporosis, bone metastasis, and giant cell tumor of bone (GCTB). RANK ligand also plays an important role in immunity by activating NF-κB and its target genes, including the osteopontin-coding gene SPP1 (also known as OPN), which is linked to CXCL9:SPP1 macrophage polarization and prognosis. In this study, we explored an additional role of denosumab in enhancing antitumor immunity in patients. Single-cell RNA sequencing was performed on nine human GCTB samples, including six untreated and three treated only with denosumab, to exclude confounding treatment factors linked with bone metastasis samples. We further analyzed paired samples collected before and after denosumab treatment from a cohort of nine patients with GCTB and conducted a pan-cancer analysis of 34 distinct types of cancers. Our single-cell analysis of GCTB resulted in a comprehensive cell atlas revealing an antitumor role of denosumab in inhibiting SPP1 expression and augmenting active cytotoxic T-cell abundance. Furthermore, we validated this immunomodulatory role of denosumab using the paired GCTB samples. Finally, the pan-cancer analysis supported a negative correlation between SPP1 and CD8A levels, with the CD8A:SPP1 ratio correlating with overall survival in 14 cancer types, which was superior to either CD8A or SPP1 alone. Our research provides clinical evidence that denosumab improves antitumor immunity by decreasing SPP1 expression and enhancing cytotoxic T-cell activity, serving as a milestone in the development of innovative use of denosumab and offering potential benefits to patients with elevated levels of SPP1.
When treating extremities affected by giant cell tumor of bone (GCTB), curettage should be performed to preserve the joint as much as possible in order to obtain a good functional outcome. The local recurrence risk is high following curettage, but new techniques are being developed to reduce local recurrence. We present a review of the literature reporting favorable results of radiofrequency ablation alone in locally recurrent small GCTB. New filling materials are also being developed to prevent non-oncological complications such as arthrosis and fractures. Routine measurement of tartrate-resistant acid phosphatase 5b in serum may be helpful in detecting early instances of local recurrence. For unresectable or metastatic GCTB, there is an urgent need for a new drug that is as effective as denosumab, avoids side effects, and can be administered to pregnant women.
Supplementary Table 1. Clinical information of giant cell of bone tumour samples for single-cell RAN sequencing. Supplementary Table 2. Clinical information of giant cell of bone tumour patients treated with denosumab.
Supplementary Figure 3. Copy number variation heterogeneity of neoplastic cells from individual patients The heatmap displays copy number variation (CNV) of individual neoplastic cells, separated by patients. Significant CNV gain was observed in chromosome 1 of M-1, M-2, and GCTB2, indicating malignant tumours. Vascular smooth muscle cells were used as a control for normal CNV. GCTB1/2 refers to giant cell tumour of bone samples from public data from reference 5.
Supplementary Figure 2. Comparison of cell-to-cell interaction between neoplastic cells and inflammatory cells in benign GCTB a. Bar charts display the outgoing (top) and incoming (bottom) information flow of neoplastic cells. The "B+" symbol represents denosumab treatment, while the "B-" symbol indicates no denosumab treatment. b. Circle plots demonstrate the cell-to-cell communication signalling network for individual pathways. The size of the vector corresponds to the interaction strength between two cell clusters.